AbCellera Biologics Inc.
ABCL
$3.65
$0.082.24%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 160.55% | 7.16% | -0.54% | -35.41% | -24.17% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 160.55% | 7.16% | -0.54% | -35.41% | -24.17% |
| Cost of Revenue | 11.70% | 7.66% | 1.20% | 5.03% | -4.78% |
| Gross Profit | 19.30% | -7.78% | -1.63% | -16.47% | -0.58% |
| SG&A Expenses | -2.64% | -0.26% | 1.91% | 8.90% | 13.72% |
| Depreciation & Amortization | -62.33% | -103.95% | -48.23% | 150.10% | 141.24% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -6.22% | -22.41% | -7.54% | 19.25% | 13.21% |
| Operating Income | 23.22% | 25.57% | 8.40% | -27.86% | -19.21% |
| Income Before Tax | 11.38% | -1.36% | -11.17% | -24.91% | -15.15% |
| Income Tax Expenses | 16.93% | -26.08% | -29.84% | -96.79% | -35.85% |
| Earnings from Continuing Operations | 10.10% | 2.34% | -8.07% | -14.28% | -11.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 10.10% | 2.34% | -8.07% | -14.28% | -11.24% |
| EBIT | 23.22% | 25.57% | 8.40% | -27.86% | -19.21% |
| EBITDA | -2.72% | 10.68% | 14.17% | 3.17% | 10.83% |
| EPS Basic | 11.37% | 3.92% | -6.32% | -12.30% | -9.28% |
| Normalized Basic EPS | 12.29% | 18.00% | -4.98% | -17.49% | -8.45% |
| EPS Diluted | 11.52% | 5.38% | -4.17% | -10.10% | -7.56% |
| Normalized Diluted EPS | 12.29% | 18.00% | -4.98% | -17.49% | -8.45% |
| Average Basic Shares Outstanding | 1.49% | 1.57% | 1.69% | 1.79% | 1.79% |
| Average Diluted Shares Outstanding | 1.49% | 1.57% | 1.69% | 1.79% | 1.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |